# Actuate 1801 Part 3B (elraglusib)

Source: https://onco.cc/trials/actuate-1801/  
OnCo record `actuate-1801` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A randomised phase 2 found that adding the GSK-3 inhibitor elraglusib to standard chemotherapy lengthened survival in metastatic pancreatic cancer; a phase 3 is needed to confirm it.

## Summary

Part 3B of the Actuate 1801 study randomised patients with previously untreated metastatic pancreatic ductal adenocarcinoma to gemcitabine and nab-paclitaxel with or without elraglusib. The company reported improved overall survival and one-year survival with elraglusib. As a phase 2 result it is hypothesis-generating, and Actuate has said a confirmatory phase 3 is planned.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-17
- Registry id: NCT03678883
- Phase: 2
- Setting: Untreated metastatic pancreatic adenocarcinoma: gemcitabine and nab-paclitaxel with or without elraglusib
- Sponsor: Actuate Therapeutics
- Result: Overall survival longer with elraglusib in a randomised phase 2; confirmation pending.

## Sources

- ClinicalTrials.gov NCT03678883: https://clinicaltrials.gov/study/NCT03678883

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Elraglusib](https://onco.cc/drugs/elraglusib/), [Gemcitabine + nab-paclitaxel](https://onco.cc/drugs/gemcitabine-nab-paclitaxel/)

---
JSON: https://onco.cc/api/v1/entities/actuate-1801.json